TY - JOUR
T1 - Integrated DNA methylation analysis reveals a potential role for ANKRD30B in Williams syndrome
AU - Kimura, Ryo
AU - Lardenoije, Roy
AU - Tomiwa, Kiyotaka
AU - Funabiki, Yasuko
AU - Nakata, Masatoshi
AU - Suzuki, Shiho
AU - Awaya, Tomonari
AU - Kato, Takeo
AU - Okazaki, Shin
AU - Murai, Toshiya
AU - Heike, Toshio
AU - Rutten, Bart P. F.
AU - Hagiwara, Masatoshi
N1 - Funding Information:
We thank the study participants, as well as the Williams Syndrome Association of Japan. We also thank Prof. Daniel H. Geschwind (Department of Neurology, David Geffen School of Medicine, University of California Los Angeles) and his staff for helpful advice on network analysis, as well as Manami Sasaki and Kei Iida for helpful technical support. This work was supported by grants-in-aid from the Japan Agency for Medical Research and Development (Grant Numbers: JP16gm0510008 to M.H. and JP18kk0305003h0003 to M.H.) and Japan Society for the Promotion of Science (Grant Numbers: 15H05721 to M.H. and 19K08251 to R.K.).
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/9
Y1 - 2020/9
N2 - Williams syndrome (WS) is a rare genetic disorder, caused by a microdeletion at the 7q11.23 region. WS exhibits a wide spectrum of features including hypersociability, which contrasts with social deficits typically associated with autism spectrum disorders. The phenotypic variability in WS likely involves epigenetic modifications; however, the nature of these events remains unclear. To better understand the role of epigenetics in WS phenotypes, we integrated DNA methylation and gene expression profiles in blood from patients with WS and controls. From these studies, 380 differentially methylated positions (DMPs), located throughout the genome, were identified. Systems-level analysis revealed multiple co-methylation modules linked to intermediate phenotypes of WS, with the top-scoring module related to neurogenesis and development of the central nervous system. Notably, ANKRD30B, a promising hub gene, was significantly hypermethylated in blood and downregulated in brain tissue from individuals with WS. Most CpG sites of ANKRD30B in blood were significantly correlated with brain regions. Furthermore, analyses of gene regulatory networks (GRNs) yielded master regulator transcription factors associated with WS. Taken together, this systems-level approach highlights the role of epigenetics in WS, and provides a possible explanation for the complex phenotypes observed in patients with WS.
AB - Williams syndrome (WS) is a rare genetic disorder, caused by a microdeletion at the 7q11.23 region. WS exhibits a wide spectrum of features including hypersociability, which contrasts with social deficits typically associated with autism spectrum disorders. The phenotypic variability in WS likely involves epigenetic modifications; however, the nature of these events remains unclear. To better understand the role of epigenetics in WS phenotypes, we integrated DNA methylation and gene expression profiles in blood from patients with WS and controls. From these studies, 380 differentially methylated positions (DMPs), located throughout the genome, were identified. Systems-level analysis revealed multiple co-methylation modules linked to intermediate phenotypes of WS, with the top-scoring module related to neurogenesis and development of the central nervous system. Notably, ANKRD30B, a promising hub gene, was significantly hypermethylated in blood and downregulated in brain tissue from individuals with WS. Most CpG sites of ANKRD30B in blood were significantly correlated with brain regions. Furthermore, analyses of gene regulatory networks (GRNs) yielded master regulator transcription factors associated with WS. Taken together, this systems-level approach highlights the role of epigenetics in WS, and provides a possible explanation for the complex phenotypes observed in patients with WS.
KW - AUTISM
KW - COGNITION
KW - BEHAVIOR
KW - DELETION
KW - GENES
U2 - 10.1038/s41386-020-0675-2
DO - 10.1038/s41386-020-0675-2
M3 - Article
C2 - 32303053
SN - 0893-133X
VL - 45
SP - 1627
EP - 1636
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 10
ER -